NetworkNewsBreaks – Predictive Oncology Inc.’s
Post# of 281
(Total Views: 306)
Posted On: 05/18/2021 4:09:00 PM
NetworkNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics CTO Discusses Revolutionizing Drug Discovery in Bell2Bell Podcast
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in a recent episode of The Bell2Bell Podcast. Predictive Oncology’s newly appointed CEO Mel Engle, CFO Bob Myers and Mark Collins, chief technical officer of the company’s Helomics subsidiary, joined the program to share financial updates, future goals and insight into current operations. The discussion also highlighted Helomics’ innovative PeDAL (patient-centric drug discovery using active learning) platform. A unique technology, PeDAL combines a proprietary, clinically validated patient tumor cell line assay with a vast knowledge base of proprietary and public data together with active learning. “What this platform does is it’s a fee-for-service platform for pharmaceutical companies to test their drugs against our cancer cell lines, like doing, if you will, a clinical trial in a plastic dish,” said Collins. “Because we have all these patient cell lines that we have knowledge of . . . what drug they were treated with and so on. And we believe this will revolutionize the way that pharma does drug discovery.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in a recent episode of The Bell2Bell Podcast. Predictive Oncology’s newly appointed CEO Mel Engle, CFO Bob Myers and Mark Collins, chief technical officer of the company’s Helomics subsidiary, joined the program to share financial updates, future goals and insight into current operations. The discussion also highlighted Helomics’ innovative PeDAL (patient-centric drug discovery using active learning) platform. A unique technology, PeDAL combines a proprietary, clinically validated patient tumor cell line assay with a vast knowledge base of proprietary and public data together with active learning. “What this platform does is it’s a fee-for-service platform for pharmaceutical companies to test their drugs against our cancer cell lines, like doing, if you will, a clinical trial in a plastic dish,” said Collins. “Because we have all these patient cell lines that we have knowledge of . . . what drug they were treated with and so on. And we believe this will revolutionize the way that pharma does drug discovery.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)